Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
galmedpharma.investorroom.com
Company Research
Source: PR Newswire
TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will present new data at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 8-12, 2019. This new pre-clinical data elucidates the mechanism by which Aramchol affects glucose metabolism in the liver that resulted in a reduction of HbA1C in patients in the Company's Phase IIb trial. The data suggests that Aramchol improves liver glucose homeostasis in patients and murine models. Galmed will also present clinical data on the rationale for the Phase 3/4 dose selection and its potential increased efficacy. "At this year's Liver Meeting, we look
Show less
Read more
Impact Snapshot
Event Time:
GLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLMD alerts
High impacting Galmed Pharmaceuticals Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GLMD
Sec Filings
- 11/22/24 - Form EFFECT
- 11/14/24 - Form 6-K
- 11/14/24 - Form F-3
- GLMD's page on the SEC website